{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T06:45:16Z","timestamp":1778568316459,"version":"3.51.4"},"reference-count":37,"publisher":"FapUNIFESP (SciELO)","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Braz J Med Biol Res"],"DOI":"10.1590\/1414-431x2024e12874","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T10:48:23Z","timestamp":1715942903000},"source":"Crossref","is-referenced-by-count":7,"title":["Trichostatin A-modified vaccine provides superior protection against ovarian cancer formation and development"],"prefix":"10.1590","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7635-0566","authenticated-orcid":false,"given":"Yingwei","family":"Liu","sequence":"first","affiliation":[{"name":"First Affiliated Hospital of Chongqing Medical University,  China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Yi","sequence":"additional","affiliation":[{"name":"Sichuan University,  China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenglan","family":"Meng","sequence":"additional","affiliation":[{"name":"Sichuan University,  China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3289-522X","authenticated-orcid":false,"given":"Xia","family":"Zhao","sequence":"additional","affiliation":[{"name":"Sichuan University,  China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiancheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Sichuan University,  China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3571-1366","authenticated-orcid":false,"given":"Yanna","family":"Zhang","sequence":"additional","affiliation":[{"name":"University of Electronic Science and Technology of China,  China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.3892\/etm.2021.10651","article-title":"Ovarian cancer health politics in Romania and Germany: a comparative study","volume":"22","author":"Cobec IM","year":"2021","journal-title":"Exp Ther Med"},{"key":"ref2","first-page":"22","article-title":"Ovarian cancer immunotherapy and personalized medicine","author":"Morand S","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-011-9289-9","article-title":"Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance","volume":"30","author":"Kandalaft LE","year":"2011","journal-title":"Cancer Metastasis Rev"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ebiom.2018.12.054","article-title":"Development and validation of an immune gene-set based prognostic signature in ovarian cancer","volume":"40","author":"Shen S","year":"2019","journal-title":"EBiomedicine"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ygyno.2020.05.681","article-title":"Immunotherapy for platinum-resistant ovarian cancer","volume":"158","author":"Bogani G","year":"2020","journal-title":"Gynecol Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.bpobgyn.2016.12.001","article-title":"Targeted therapies for ovarian cancer","volume":"41","author":"Grunewald T","year":"2017","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"577869","DOI":"10.3389\/fimmu.2020.577869","article-title":"Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvant","volume":"11","author":"Yang C","year":"2020","journal-title":"Front Immunol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ygyno.2019.11.011","article-title":"Sunset, or dawn of a new age for ovarian cancer vaccine therapy?","volume":"155","author":"Hinchcliff E","year":"2019","journal-title":"Gynecol Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.7774\/cevr.2022.11.2.163","article-title":"Formulation of an ovarian cancer vaccine with the squalene-based AddaVax adjuvant inhibits the growth of murine epithelial ovarian carcinomas","volume":"11","author":"Mazumder S","year":"2022","journal-title":"Clin Exp Vaccine Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1001\/jama.2018.10822","article-title":"Pursuing an effective ovarian cancer vaccine","volume":"320","author":"Voelker R","year":"2018","journal-title":"Jama"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1016\/j.vaccine.2015.07.094","article-title":"Mapping T and B cell epitopes in sperm protein 17 to support the development of an ovarian cancer vaccine","volume":"33","author":"Xiang SD","year":"2015","journal-title":"Vaccine"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41551-021-00795-w","article-title":"Cancer vaccines from cryogenically silicified tumour cells functionalized with pathogen-associated molecular patterns","volume":"6","author":"Guo J","year":"2022","journal-title":"Nat Biomed Eng"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4161\/hv.26568","article-title":"Allogeneic tumor cell vaccines: the promise and limitations in clinical trials","volume":"10","author":"Srivatsan S","year":"2014","journal-title":"Hum Vacc Immunother"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e78417","DOI":"10.1371\/journal.pone.0078417","article-title":"Expression loss and revivification of RhoB gene in ovary carcinoma carcinogenesis and development","volume":"8","author":"Liu Y","year":"2013","journal-title":"Plos One"},{"key":"ref15","first-page":"4561","article-title":"Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer","volume":"60","author":"Mariadason JM","year":"2000","journal-title":"Cancer Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.3892\/ijo.2015.3192","article-title":"Radiation-induced modulation of immunogenic genes in tumor cells is regulated by both histone deacetylases and DNA methyltransferases","volume":"47","author":"Cacan E","year":"2015","journal-title":"Int J Oncol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12026-007-0085-0","article-title":"Histone deacetylase regulation of immune gene expression in tumor cells","volume":"40","author":"Khan AN","year":"2008","journal-title":"Immunol Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1479-5876-5-64","article-title":"An epigenetic vaccine model active in the prevention and treatment of melanoma","volume":"5","author":"Khan AN","year":"2007","journal-title":"J Transl Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1021\/acsmedchemlett.9b00579","article-title":"Design, synthesis, and preliminary immunological studies of MUC1-based antitumor vaccines adjuvanted with R- and S-FSL-1","volume":"11","author":"Liu Y","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"384","DOI":"10.21037\/atm.2017.09.09","article-title":"New trends in antitumor vaccines in melanoma","volume":"5","author":"Vasquez M","year":"2017","journal-title":"Ann Transl Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1002\/asia.201900448","article-title":"Liposomal antitumor vaccines targeting mucin 1 elicit a lipid-dependent immunodominant response","volume":"14","author":"Du JJ","year":"2019","journal-title":"Chem Asian J"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.3389\/fimmu.2019.03117","article-title":"Editorial: novel strategies for anti-tumor vaccines","volume":"10","author":"Accolla RS","year":"2019","journal-title":"Front Immunol"},{"key":"ref23","first-page":"690","article-title":"Tumor vaccines-therapeutic vaccination against cancer [in German]","volume":"61","author":"Rammensee HG","year":"2020","journal-title":"Internist (Berl)"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"584367","DOI":"10.3389\/fonc.2020.584367","article-title":"Enhancing the efficacy of tumor vaccines based on immune evasion mechanisms","volume":"10","author":"Chen J","year":"2021","journal-title":"Front Oncol"},{"key":"ref25","first-page":"1413","article-title":"Epigenetic remodelling of DNA in cancer","volume":"22","author":"Lettini AA","year":"2007","journal-title":"Histol Histopathol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00262-006-0164-4","article-title":"Epigenetic regulation of immune escape genes in cancer","volume":"55","author":"Tomasi TB","year":"2006","journal-title":"Cancer Immunol Immun"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/bjc.1982.114","article-title":"Mononuclear-cell infiltration in ovarian cancer. I. Inflammatory-cell infiltrates from tumour and ascites material","volume":"45","author":"Haskill S","year":"1982","journal-title":"Br J Cancer"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"101437","DOI":"10.1016\/j.smim.2020.101437","article-title":"Adoptive T cell therapy: boosting the immune system to fight cancer","volume":"49","author":"Leon E","year":"2020","journal-title":"Semin Immunol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2009-03-208249","article-title":"Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments","volume":"114","author":"Kryczek I","year":"2009","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"10299","DOI":"10.7314\/APJCP.2014.15.23.10299","article-title":"Epigenetic changes within the promoter regions of antigen processing machinery family genes in Kazakh primary esophageal squamous cell carcinoma","volume":"15","author":"Sheyhidin I","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.smim.2010.02.004","article-title":"Whole tumor antigen vaccines","volume":"22","author":"Chiang CL","year":"2010","journal-title":"Semin Immunol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/vaccines3020344","article-title":"Whole tumor antigen vaccines: where are we?","volume":"3","author":"Chiang CL","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/sj.cdd.4402201","article-title":"Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis","volume":"14","author":"Obeid M","year":"2007","journal-title":"Cell Death Differ"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.2147\/OTT.S97587","article-title":"Antitumor activity of pluripotent cell-engineered vaccines and their potential to treat lung cancer in relation to different levels of irradiation","volume":"9","author":"Zhang YN","year":"2016","journal-title":"Onco Targets Ther"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1101\/gad.1134603","article-title":"RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development","volume":"17","author":"Adini I","year":"2003","journal-title":"Gene Dev"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1128\/MCB.24.12.5565-5576.2004","article-title":"Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis","volume":"24","author":"Jiang K","year":"2004","journal-title":"Mol Cell Biol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1158\/0008-5472.CAN-08-4147","article-title":"Loss of RhoB expression promotes migration and invasion of human bronchial cells via activation of AKT1","volume":"69","author":"Bousquet E","year":"2009","journal-title":"Cancer Res"}],"container-title":["Brazilian Journal of Medical and Biological Research"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0100-879X2024000100634&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T10:48:40Z","timestamp":1715942920000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0100-879X2024000100634&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":37,"alternative-id":["S0100-879X2024000100634"],"URL":"https:\/\/doi.org\/10.1590\/1414-431x2024e12874","relation":{},"ISSN":["1414-431X","0100-879X"],"issn-type":[{"value":"1414-431X","type":"electronic"},{"value":"0100-879X","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e12874"}}